1. Home
  2. VRSN vs ONC Comparison

VRSN vs ONC Comparison

Compare VRSN & ONC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo VeriSign Inc.

VRSN

VeriSign Inc.

HOLD

Current Price

$307.05

Market Cap

28.2B

Sector

Technology

ML Signal

HOLD

ONC

BeiGene Ltd. American Depositary Shares

HOLD

Current Price

$304.29

Market Cap

31.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VRSN
ONC
Founded
1995
2010
Country
United States
Switzerland
Employees
N/A
12000
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
28.2B
31.4B
IPO Year
1997
N/A

Fundamental Metrics

Financial Performance
Metric
VRSN
ONC
Price
$307.05
$304.29
Analyst Decision
Buy
Strong Buy
Analyst Count
3
10
Target Price
$317.67
$385.10
AVG Volume (30 Days)
634.9K
204.1K
Earning Date
04-23-2026
05-06-2026
Dividend Yield
1.19%
N/A
EPS Growth
N/A
N/A
EPS
6.24
N/A
Revenue
$1,656,600,000.00
N/A
Revenue This Year
$6.78
$723.76
Revenue Next Year
$5.37
$15.04
P/E Ratio
$49.69
$614.06
Revenue Growth
6.37
N/A
52 Week Low
$209.34
$235.94
52 Week High
$312.48
$385.22

Technical Indicators

Market Signals
Indicator
VRSN
ONC
Relative Strength Index (RSI) 73.13 49.04
Support Level $257.67 $295.20
Resistance Level N/A $308.99
Average True Range (ATR) 8.09 8.77
MACD 1.37 0.07
Stochastic Oscillator 87.59 43.81

Price Performance

Historical Comparison
VRSN
ONC

About VRSN VeriSign Inc.

Verisign is an operator of critical infrastructure within the domain name system, or DNS. As the registry for some of the world's most popular TLDs, .com and .net, Verisign directs DNS resolvers to the appropriate registry where IP addresses are stored. Verisign's control over its TLDs is regulated by ICANN and the NTIA and are subject to contract renewal every six years. The company generates revenue through annual subscriptions allowing customers to use .com and .net as their TLD of choice for their respective websites.

About ONC BeiGene Ltd. American Depositary Shares

BeOne Medicines Ltd is a holding company. Through its subsidiaries, it operates as an oncology-focused biopharmaceutical company engaged in the discovery and development of treatments for cancer. Its portfolio includes BRUKINSA (a Bruton's tyrosine kinase (BTK) inhibitor), sonrotoclax (a B-cell lymphoma 2 (BCL2) inhibitor, and a BTK chimeric degradation activation compound (BTK-CDAC). The company develops and commercializes wholly owned therapeutic assets targeting multiple mechanisms of action in oncology. The company operates in one segment: pharmaceutical products. It generates the majority of its revenue from the sale of its biopharmaceutical products.

Share on Social Networks: